Latest News

Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS – [Cloned #5940]
Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS Obstructive hypertrophic cardiomyopathy (HCM) is a disease state that has experienced a boom in

Newly reported from EULAR 2024: Long COVID Linked to Significantly Worse Rheumatic Disease Activity
Newly reported from EULAR 2024: Long COVID Linked to Significantly Worse Rheumatic Disease Activity COVID-19 has demonstrated a substantial impact on patients with inflammatory arthritis, with those experiencing “long COVID”

News Coverage from EULAR 2024: Arthritis Disease Severity Peaks in Spring and Fall, According to PROs
News Coverage from EULAR 2024: Arthritis Disease Severity Peaks in Spring and Fall, According to PROs A seasonal correlation with patient-reported outcomes (PROs) were impacted by factors like sleep and

Broadcasting from EULAR 2024: Anxiety Plays a Significant Role in Physical Activity Avoidance Among Patients with PsA
Broadcasting from EULAR 2024: Anxiety Plays a Significant Role in Physical Activity Avoidance Among Patients with PsA Patients with psoriatic arthritis (PsA) were more likely to avoid physical activity based on

Newly reported from EULAR 2024: Ketogenic Diet Intervention Improves Psoriatic Arthritis Symptoms
Newly reported from EULAR 2024: Ketogenic Diet Intervention Improves Psoriatic Arthritis Symptoms A very low-calorie ketogenic diet (VLCKD) resulted in improvements in skin and joint disease activity, lipid profile, and

Reporting from EULAR 2024: Gout Remission Achieved in Approximately Half of Patients Treated with Pegloticase
Reporting from EULAR 2024: Gout Remission Achieved in Approximately Half of Patients Treated with Pegloticase In a post hoc analysis of the MIRROR randomized controlled trial, 47% of patients with gout treated

Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch A real-world study showed patients with inflammatory bowel disease (IBD) or chronic inflammatory rheumatic disease treated

News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months
News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence, as well as equivalent efficacy,

Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren’s Treatment
Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren’s Treatment In an interview with HCPLive, Jacques-Eric Gottenberg, MD, PhD, associated with the Department